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Abstract 
Pulmonary involvement in the course of systemic senile amyloidosis caused by non-mutated transthyretin is rarely described. 
We report on concomitant monoclonal gammapathy of undermined significance (MGUS) and amyloidosis with non-mutated 
transthyretin with diffuse lesions in lung parenchyma.
A female patient, 67 years old, was admitted with dyspnoea, malaise, weight loss, and disseminated radiological lesions in the lungs.
On lung HRCT, signs of pulmonary hypertension, alveolar and interstitial involvement, with thickening of septal lines were found.
Echocardiography revealed severe pulmonary hypertension, and electromyography revealed sensoromotoric polyneuropathy with 
axon and myelin damage.
Pathological assessment of lung specimens revealed nodular deposits of amyloid in the bronchial walls and lung parenchyma 
Congo red staining was positive. Specimens of colon mucosa confirmed amyloidosis. Stainings for AA, AL and beta2-microglo-
bulin were negative but were positive for transthyretin. Bone marrow trepanobiopsy indicated monoclonal gammapathy of MGUS 
type; Congo red staining was positive.
Transthyretin amyloidosis with vascular involvement, particularly of arteriovenous anastomoses, including pulmonary vessels 
and an insignificant amount of AL protein (perhaps secondary imbibition with AL protein from serum) was diagnosed in amyloid 
deposits. No mutations of the transthyretin gene (exon 1,2,3,4) were found. 
The patient was treated with methylprednisolone, melphalan and then with cyclophosphamide. Radiological examinations per-
formed 1 and 2 month/s after initiation of therapy showed progression of pulmonary lesions. The patient died one month later; 
an autopsy was not performed.
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Streszczenie
Zmiany płucne w przebiegu starczej amyloidozy z niezmutowanej transtyretyny są rzadko opisywane. Opisywany przypadek dotyczy współ-
istnienia gammapatii monoklonalnej typu MGUS oraz amyloidozy z niezmutowanej transtyretyny z rozległym zajęciem miąższu płucnego.
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Introduction
Amyloidosis is characterised by localized 
or systemic occurrence of amyloid deposits. The 
lungs may be involved in localized or systemic 
occurrence of amyloid deposits [1]. Pulmonary 
manifestations in the course of systemic amy-
loidosis caused by non-mutated transthyretin, 
a transport protein for thyroxine and retinol in 
plasma, are rarely reported. Lung involvement is 
seen more frequently in light chains amyloidosis 
(AL) [2]. Typical pulmonary lesions occurring in 
amyloidosis include localized nodules and diffuse 
infiltrates of alveolar septa [1–3]. The authors 
present a case report of concomitant MGUS-type 
(monoclonal gammapathy of underdetermined 
significance) monoclonal gammapathy and amy-
loidosis caused by non-mutated transthyretin 
with diffuse involvement of lung parenchyma.
Case Report
A female patient (G.K.), 67 years old, was 
admitted to the Division of Respiratory Diseases, 
University Hospital, Krakow, Poland, with symp-
toms of resting dyspnoea, malaise and weight loss 
progressing during the preceding few months. The 
patient status showed undernutrition (BMI 19). 
Chest examination revealed diastolic heart mur-
mur in the pulmonary valve area and bibasilar 
rales. Arterial blood pressure was 160/100 mm 
Hg. Arterial blood gases indicated hypoxemic 
respiratory failure with pH 7.43, PaO2 51.3 mm 
Hg and PaCO2 34.1 mm Hg. Pulmonary function 
tests showed a  restriction pattern: FVC 59.8%, 
FEV1 57.6% of predicted value, FEV1/FVC 0.80 
and TLCOc/VA 59.8 mmoL/min/kPa/L.
Laboratory assessment confirmed the pre-
sence of monoclonal protein in serum at con-
Sześćdziesięciosiedmioletnia kobieta została przyjęta na ddział z objawami duszności, osłabienia, utraty masy ciała oraz zmianami 
rozsianymi w płucach. W badaniu HRCT obecne były obszary wypełnień pęcherzykowych, pogrubienie linii przegrodowych oraz 
cechy nadciśnienia płucnego. W ECHO serca stwierdzono cechy znacznego nadciśnienia płucnego, badaniem elektromiograficz-
nym czuciowo-ruchową polineuropatię z uszkodzeniem aksonu i mieliny.
Wykazano złogi amyloidu w formie guzków w ścianach oskrzeli oraz zrębie płuca, barwienie na czerwień Congo było dodatnie, ujem-
ne dla białek AA, AL, beta2-mikroglobuliny, dodatnie dla transtyretyny. Amyloidozę potwierdzono również ze śluzówki jelita (ujemne 
barwienie dla białek AA, AL., beta2-mikroglobuliny, dodatnie dla transtyretyny). Trepanobiopsja szpiku wykazała gammapatię mo-
noklonalną typu MGUS z dodatnim barwieniem na czerwień Congo. U chorej postawiono rozpoznanie amyloidozy z transtyretyny 
z zajęciem naczyń, w szczególności połączeń tętniczo-żylnych, w tym także płucnych z niewielką ilością białka AL (najpewniej była 
to wtórna imbibicja z surowicy krwi). Nie stwierdzono mutacji w egzonie 1, 2, 3, 4 dla genu transtyretyny. Pacjentka była leczona 
metyloprednisolonem, melfalanem oraz cyklofosfamidem. Zdjęcie przeglądowe klatki piersiowej wykonane 1 i 2 miesiące po roz-
poczęciu terapii wykazało progresję zmian. Pacjentka zmarła w szpitalu rejonowym – sekcji zwłok nie wykonano.
Słowa kluczowe: amyloidoza, MGUS, transtyretyna, manifestacje płucne, niewydolność oddechowa
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Figure 1. Chest X-ray showing diffuse reticulo-nodular lesions in the lungs
centration 16.2 g/L (total protein was 70.0 g/L), 
monoclonal protein in urine — kappa (κ) chains 
37.4 mg/L (normal level: <7.08 mg/L), lambda 
(λ) chains 62.8 mg/L (normal level <3.89 mg/L), 
increased TSH level in serum (6.58 IU/mL, normal 
level 0.35 – 4.94 IU/mL) and decreased prealbu-
min level (0.170 g/L, normal level 0.18–0.36 g/L).
Chest X-ray revealed diffuse reticulo-nodu-
lar lesions in the lungs (Fig. 1). High resolution 
computed tomography (HRCT) showed thicke-
ning of septal lines, and areas of alveolar opa-
cities and symptoms of alveolar and interstitial 
oedema (Fig. 2). Contrast-enhanced computed 
tomography demonstrated enlarged para-aortic 
and subcarinal lymph nodes. The features of the 
pulmonary hypertension were found with echo-
cardiography: systolic pulmonary pressure of 95 
mm Hg, considerably widened right ventricle and 
right atrium, paradoxical movement and shift to 
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left of interventricular septum and small left ven-
tricle. Ejection fraction (EF) was 65%. Pulmonary 
angiography did not reveal embolic material in 
the pulmonary arteries, and this finding was con-
cordant with the perfusion scintigraphy result.
As the patient complained of sensory pa-
raesthesia of upper limbs, electromyography 
(EMG) was performed. It confirmed the presence 
of sensomotoric polyneuropathy with axon and 
myelin damage.
Bronchofiberoscopy with bronchial and 
transbronchial lung biopsy was performed.
Histopathological assessment of the biopsy 
samples revealed bronchial and lung amyloidosis 
with amyloid deposits in the form of nodules in the 
bronchial walls, lung parenchyma and arteriovenous 
anastomoses. Congo red staining (Fig. 3) as well as 
staining for transthyretin were positive (Fig. 4), but 
stainings for amyloid of serum protein A (AA) and for 
amyloid of light immunoglobulin chains (AL) were 
negative. A biopsy of rectal mucosa was also carried 
out and a similar staining pattern was obtained.
Following haematological consultation, the 
patient underwent trepanobiopsy of bone marrow, 
and MGUS-type monoclonal gammapathy was 
diagnosed. Congo red staining of the bone marrow 
biopsy specimen was also positive.
Thus the histopathological assessment of 
biopsies (lung, bronchi, colon mucosa, bone 
marrow) suggested transthyretin amyloidosis 
with vascular involvement with arterio-venous 
anastomoses, particularly in the lungs. A small 
amount of AL protein was also found in the amy-
loid deposits, but it was difficult to decide if this 
finding supported diagnosis of a complex type 
of amyloidosis or it was a result of a secondary 
infiltration with AL protein present in the serum.
Figure 3. Positive Congo red staining in lung parenchyma in a speci-
men taken from the patient
Figure 2. The HRCT scan with thickening of septal lines, areas of 
alveolar opacities and symptoms of alveolar and interstitial oedema
Figure 4. A specimen of lung parenchyma with positive staining for 
transthyretin
Genetic analysis was performed in order 
to determine the presence of mutations of the 
transthyretin gene (TTR, OMIM176300). The 
assessment of exons 2, 3 and 4 was performed 
in the Immunology Department, Hospital Clinic 
in Barcelona, Spain. After amplification with 
the PCR method, the Sanger method for direct 
sequencing of 2, 3 and 4 exons of the TTR gene 
was applied. The same approach was used for 
the analysis of exon 1 of the TTR gene in our 
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Laboratory of Molecular Biology and Clinical 
Genetics, Department of Medicine, Jagiellonian 
University Medical College, Krakow, Poland. No 
nucleotide changes that could be responsible for 
hereditary transthyretin amyloidosis were found 
in these four exons.
The patient was ordered chemotherapy 
with a  regimen including methylprednisolone, 
melphalan, and cyclophosphamide. After two 
months of therapy, the patient was admitted to 
the Division of Respiratory Diseases because of 
severe respiratory failure (PaO2 31.8 mm Hg, 
PaCO2 40 mm Hg). The laboratory results revealed 
a decrease of serum level of monoclonal prote-
in (14.3 g/L) as well as κ and λ chains levels in 
urine (25.4 and 49.5 mg/L, respectively). Chest 
X-ray and HRCT showed intensive progression 
of interstitial lesions in the lungs. A further in-
crease of pulmonary artery pressure to 100 mm 
Hg was confirmed with echocardiography. There 
were no symptoms of pulmonary embolism in CT 
angiography. Bacterial cultures from bronchial 
washings were negative. The patient was treated 
with clarithromycin, calcium channel blocker, 
beta-blocker, angiotensin-converting enzyme 
inhibitor, diuretics and oxygen therapy. Impro-
vement of the patient’s status and arterial blood 
gases was achieved, but there was no change in 
radiological image. The patient was discharged 
from the Division of Respiratory Diseases for 
further ambulatory treatment and long-term 
oxygen therapy at home. One month later the 
patient was admitted to the regional hospital with 
symptoms of severe respiratory failure and died 
despite symptomatic treatment. An autopsy was 
not performed at the family’s request.
Discussion
Amyloidosis is characterised by the presen-
ce of extracellular deposits of insoluble fibrillar 
protein in one or many organs. Amyloid deposits 
are identified under polarized light as they yield 
green birefringence following Congo red staining. 
Furthermore, under electron microscopy they are 
seen as straight, non-branching fibrillae of length 
8-10 nm. Fibrillae are composed of 5–25 kD su-
bunits of various circulating plasma proteins. At 
present, about 25 amyloid protein precursors have 
been identified. The classification of amyloidosis 
is based on identification of these precursors [4, 5].
The two most common types of systemic 
amyloidosis are light chain amyloidosis (AL) with 
a prevalence of 1 case per 100 000 and secondary 
(reactive) amyloidosis (AA) caused by chronic 
inflammatory diseases (e.g. rheumatoid polyar-
thritis, chronic infections) [4–6].
Familial amyloidosis is a group of hereditary 
disorders with an autosomal dominant mode of 
inheritance. Amyloid fibrillae are formed from 
mutated proteins, and the process usually starts in 
middle age (4th or 5th decade). The most common 
type of familial amyloidosis is caused by mutated 
transthyretin. Other types of hereditary amyloidosis 
result from mutation of apolipoprotein A-I, gelsoline, 
alpha chains of fibrinogen A and lysozyme [4, 7–10].
Senile systemic amyloidosis prevails in sub-
jects above 75 years old and is associated with 
systemic deposition of non-mutated, transthyretin 
(mainly in the heart and blood vessels) [4, 9–11].
Clinical symptoms depend on the type of pre-
cursor protein, its tissue deposition and the amount 
of amyloid. In the two main types of amyloidosis, 
primary (AL) and secondary (AA), amyloid accu-
mulates mainly in the kidneys, heart, liver and 
nervous system and leads to organ failure [4, 9].
The respiratory system is usually involved 
in AL amyloidosis. It results in the occurrence 
of tracheobronchial infiltrates, nodular lesions 
or alveolar filling deposits in lung parenchyma, 
pleural effusion and/or mediastinal lymph node 
involvement [3, 4, 9]. Multifocal submucosal 
infiltrates, nodules or tumour-like structures are 
typical for tracheobronchial disease. This type of 
amyloidosis often coexists with osteoplastic tra-
cheobronchopathy. Clinical manifestations include 
dyspnoea, cough and haemoptysis. Pulmonary di-
sease is frequently accompanied by amyloidosis of 
other organs. The radiological nodular or alveolar 
filling pattern may resemble other interstitial lung 
diseases or pulmonary oedema. Involvement of 
the lymphatic system is typically associated with 
amyloid deposits in mediastinal lymph nodes. 
It may accompany a B-cell lymphoma. Involved 
lymph nodes may contain calcifications [9]. Lungs 
are extremely rarely involved in AA, and hereditary 
types of [2] amyloidosis caused by mutated tran-
sthyretin (equivalent for prealbumin) affect mainly 
the heart. It may also lead to familial polyneuropa-
thy or nephropathy [4, 5, 7–9, 11].
Pulmonary involvement may also occur in 
senile systemic amyloidosis caused by deposits 
of non-mutated transthyretin in heart, kidneys, 
and intestine. This type of amyloidosis is found 
mainly in elderly patients, usually above 75 years 
old [4, 9–11]. In the reported case of a 67-year-old 
female patient, we investigated clinical and radio-
logical features of interstitial lung disease with 
increased serum level of monoclonal protein and 
increased urine levels of λ and κ chains. Histo-
Katarzyna Kruczak i wsp., Amyloidosis and monoclonal gammapathy
541www.pneumonologia.viamedica.pl
pathological assessment of the samples obtained 
with bronchial and transbronchial lung biopsy 
yielded the diagnosis of amyloidosis caused 
by transthyretin deposits (positive Congo red 
staining, negative staining for AL and AA). The 
diagnosis was confirmed by histopathological as-
sessment of colon mucosa biopsy. Trepanobiopsy 
of bone marrow yielded a diagnosis of MGUS; 
staining with Congo red was also positive.
MGUS is the form of monoclonal gamma-
pathy associated with paraproteinemia. MGUS 
occurs in 1–2% of patients above 60 years old and 
in 4–5% of those above 80 years old. Annual risk 
of neoplastic transformation is 1%. It is charac-
terised by the lack of lytic lesions in bones, no 
symptoms of chronic infections, IgG M-compo-
nent < 30 g/L, and percentage of clonal plasma 
cells in bone marrow < 10% [12].
The criteria for diagnosis of multiple myelo-
ma were not fulfilled in our patient. After haema-
tological referral, chemotherapy was initiated in 
the patient because of diffuse organ involvement. 
Following two series of chemotherapy, the pro-
gression of pulmonary lesions was observed even 
though a decrease of serum monoclonal protein 
and urine levels of kappa and lambda chains was 
obtained. The patient died with symptoms of cir-
culatory and respiratory failure. While discussing 
differential diagnosis, we assumed that MGUS wo-
uld be an improbable cause of pulmonary lesions 
leading to respiratory failure and severe pulmonary 
hypertension in this patient. Histochemical tests 
were positive for transthyretin. Although a small 
amount of AL protein was found in amyloid depo-
sits, it could be probably attributed to secondary 
imbibition of plasma AL protein. Chemotherapy 
did not bring any improvement in lung involve-
ment; on the contrary, rapid progression was ob-
served during the treatment. We believe that the 
patient, despite her relatively young age (67 years 
old), suffered from systemic senile amyloidosis 
with associated involvement of bronchial walls and 
lung parenchyma, as well as the presence of arte-
rio-venous anastomoses, which were responsible 
for the severe pulmonary hypertension observed in 
advanced amyloidosis [13]. Amyloid deposits were 
also present in the gastrointestinal tract.
Pulmonary hypertension in patients with amy-
loidosis is most frequently caused by restrictive 
cardiomyopathy related to involvement of the left 
ventricle. In our patient the left ventricle was not 
compromised by amyloidosis. Thus, hypoxaemia 
resulting form amyloid interstitial infiltrations of 
interstitial lung tissue remains the most probable 
cause. However, pulmonary hypertension in amy-
loidosis may also occur without involvement of the 
left ventricle or lung interstitium [14].
It is also possible that the patient was affec-
ted by mixed type amyloidosis caused by light 
chains and non-mutated transthyretin despite 
the low amount of AL amyloid in pulmonary 
tissue. This could be related to a loss of amyloid 
epitopes leading to insufficient immunohistoche-
mical reactions. Cases of amyloidosis associated 
with simultaneous occurrence of light chains and 
mutated transthyretin deposits were reported 
in literature [15]. Similar phenomenon could 
possibly occur in senile systemic amyloidosis. 
Unfortunately, an autopsy was not performed on 
the patient and this precluded ultimate diagnosis.
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